Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Pain; swelling; This non-serious case was reported by a consumer via call center representative and described the occurrence of pain in a patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included mucinous breast carcinoma. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced pain (Verbatim: Pain) and swelling (Verbatim: swelling). The outcome of the pain and swelling were not reported. It was unknown if the reporter considered the pain and swelling to be related to Shingrix. It was unknown if the company considered the pain and swelling to be related to Shingrix. Additional Information: GSK Receipt Date: 21-FEB-2025 The reporter reported a chatbot conversation in which the patient reported that he/she was currently being treated for mucinous carcinoma of the breast. Patient had his first Shingrix shot the day before his/her biopsy. Patient asked that could he/she take Shingrix while being treated for mucinous carcinoma. Also, had the first shot and experienced pain, swelling.
Mucinous breast carcinoma